This competitive renewal application proposes to investigate the downstream mechanisms by which ROCK regulates eNOS mRNA stability and activity. Preliminary studies suggest that phosphorylation of the translational elongation factor-1? (eEF1A) by ROCK2 leads to decreased eNOS mRNA stability and expression. Furthermore, we found that activation of Phosphatase and TENsin homologue (PTEN) by ROCK2 leads to decreased phosphatidylinositol 3,4,5-trisphosphate (PtdIns-3,4,5-P3) levels and inhibition of Akt-mediated eNOS activity. Based upon these pilot studies, two comprehensive specific aims are proposed, which will determine how the regulation of eEF1A and PTEN by ROCK2 could affect eNOS expression and activity, respectively, and whether this contributes importantly to the pathogenesis of endothelial dysfunction and vascular disease. It is hoped that these studies will help establish the importance of ROCK2 as a therapeutic targets for improving endothelial function and decreasing cardiovascular disease.
Specific aim 1 : To determine whether ROCK2 regulates endothelial function in vivo, we will generate endothelial-specific ROCK2Tie2-/- and EC-caROCK mice, and investigate whether eNOS expression, endothelium-dependent vascular relaxation, and atherosclerosis are altered due to the loss- or gain-of-function of endothelial ROCK2. Further studies are proposed to determine how phosphorylation of eEF1A by ROCK2 leads to eNOS mRNA instability and decreased eNOS expression.
Specific aim 2 : To determine how ROCK2 could inhibit the Akt/eNOS pathway, we will investigate how ROCK2 decreases PIP3 levels through inhibition of PI3K activity, stimulation of PTEN activity, or both. We will determine whether ROCK2 can bind to and phosphorylate PTEN, and identify putative ROCK phosphorylation site(s) on PTEN. We will then determine whether phosphorylation of PTEN by ROCK2 increases PTEN activity, leading to decreased PIP3 levels and inhibition of Akt Thr308 phosphorylation and activity. These findings will be correlated with Akt-dependent eNOS Ser1179 phosphorylation and the degree of vascular remodeling.
Cardiovascular disease is a major cause of morbidity and mortality worldwide. The underlying mechanism is partly due to endothelial dysfunction. This research application proposes to investigate the role of an emerging signaling pathway, Rho kinase (ROCK), as an important regulator of endothelial function in vascular disease.
|Zee, Robert Y L; Wang, Qing-Mei; Chasman, Daniel I et al. (2014) Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study. Clin Sci (Lond) 126:829-35|
|Sawada, Naoki; Liao, James K (2014) Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal 20:1251-67|
|Miao, Yanying; Liao, James K (2014) Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother 14:173-85|
|Kajikawa, Masato; Noma, Kensuke; Maruhashi, Tatsuya et al. (2014) Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension 63:856-64|
|Toque, Haroldo A; Nunes, Kenia P; Yao, Lin et al. (2013) Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J Sex Med 10:1502-15|
|Dong, Ming; Jiang, Xin; Liao, James K et al. (2013) Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease. Clin Cardiol 36:347-51|
|Liao, James K (2013) Linking endothelial dysfunction with endothelial cell activation. J Clin Invest 123:540-1|
|Tanaka, Shin-ichi; Fukumoto, Yoshihiro; Nochioka, Kotaro et al. (2013) Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol 33:1591-600|
|Montalvo, J; Spencer, C; Hackathorn, A et al. (2013) ROCK1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression. Curr Mol Med 13:205-19|
|Okamoto, Ryuji; Li, Yuxin; Noma, Kensuke et al. (2013) FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 27:1439-49|
Showing the most recent 10 out of 111 publications